122 related articles for article (PubMed ID: 25385734)
1. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?
Aragon-Ching JB
J Clin Oncol; 2014 Dec; 32(36):4169-70. PubMed ID: 25385734
[No Abstract] [Full Text] [Related]
2. Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.
Adesunloye BA
J Clin Oncol; 2014 Dec; 32(36):4170. PubMed ID: 25385733
[No Abstract] [Full Text] [Related]
3. Everything old is new again! Neoadjuvant chemotherapy in the treatment of muscle-invasive bladder cancer.
Sternberg CN; Apolo AB
J Clin Oncol; 2014 Jun; 32(18):1868-70. PubMed ID: 24821880
[No Abstract] [Full Text] [Related]
4. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
Pouessel D; Gauthier H; Serrate C; Pfister C; Culine S
J Clin Oncol; 2014 Dec; 32(36):4168-9. PubMed ID: 25385728
[No Abstract] [Full Text] [Related]
5. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Plimack ER; Hoffman-Censits J; Rosenberg JE; Wong YN; Bellmunt J; Choueiri TK
J Clin Oncol; 2014 Dec; 32(36):4171-2. PubMed ID: 25385730
[No Abstract] [Full Text] [Related]
6. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Sternberg CN; Apolo AB
J Clin Oncol; 2014 Dec; 32(36):4172-3. PubMed ID: 25385726
[No Abstract] [Full Text] [Related]
7. Bladder cancer: accelerating MVAC.
Killock D
Nat Rev Clin Oncol; 2014 Jul; 11(7):378. PubMed ID: 24863165
[No Abstract] [Full Text] [Related]
8. Bladder cancer: Accelerating MVAC.
Killock D
Nat Rev Urol; 2014 Jun; 11(6):307. PubMed ID: 24861327
[No Abstract] [Full Text] [Related]
9. Re: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Chang SS
J Urol; 2015 Jun; 193(6):1932. PubMed ID: 25986790
[No Abstract] [Full Text] [Related]
10. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.
Plimack ER; Hoffman-Censits JH; Viterbo R; Trabulsi EJ; Ross EA; Greenberg RE; Chen DY; Lallas CD; Wong YN; Lin J; Kutikov A; Dotan E; Brennan TA; Palma N; Dulaimi E; Mehrazin R; Boorjian SA; Kelly WK; Uzzo RG; Hudes GR
J Clin Oncol; 2014 Jun; 32(18):1895-901. PubMed ID: 24821881
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
[TBL] [Abstract][Full Text] [Related]
12. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
13. Neoadjuvant chemotherapy for bladder cancer.
Sonpavde G; Lerner SP
Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?
Mazhar D; Ali N; Ngan S
Future Oncol; 2007 Feb; 3(1):5-8. PubMed ID: 17280495
[No Abstract] [Full Text] [Related]
15. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
16. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
[No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant chemotherapy: meta-analysis and interpretation of results in bladder cancer].
Pollera CF
Suppl Tumori; 2004; 3(4):S59-61. PubMed ID: 15206215
[No Abstract] [Full Text] [Related]
19. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation.
Sternberg CN
Semin Oncol; 2007 Apr; 34(2):122-8. PubMed ID: 17382795
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy of carcinoma of the bladder.
deVere White RW
Semin Urol; 1990 Aug; 8(3):197-200. PubMed ID: 2204981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
